Analyst Reports

  • 16 Oct 2019

    Edison Investment Research
    Actinogen Medical: Well-timed XanaHES study saves the day

    Analyst: Jonas Peculias

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 08 May 2019

    Edison Investment Research
    Phase II XanADu trial results

    Analyst: Jonas Peculias

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 18 Mar 2019

    Edison Investment Research
    Differentiated treatment for Alzheimer’s disease

    Analyst: Jonas Peculias

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison. The report solely reflects the views of Edison.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report

Latest results

Half Year Financial
Report to 31 Dec 2021

View Results Centre

2021 Annual General Meeting

Actinogen’s Annual General Meeting was held on 10 November 2021.

Read more

Back
to top